Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .
Effect of naftopidil on nocturia after failure of tamsulosin.
OBJECTIVES The clinical usefulness of naftopidil was evaluated in 122 patients with benign prostatic hyperplasia for urinary tract symptoms and signs , focused in particular on nocturia . METHODS A total of 122 patients with BPH whose symptoms did not improve after 6 weeks of tamsulosin administration were enrolled . After the treatment was followed by a washout period with placebo , patients were prescribed 75 mg of naftopidil to be taken after dinner for 6 weeks , and the efficacy was re-evaluated . All the drugs used were unidentified , and attention was given to not have the patients recognize the change in the drug given . The primary purpose of this study was the improvement of nocturia in patients with a poor response to tamsulosin . The clinical efficacy of naftopidil was defined as significant improvement in International Prostate Symptom Score , quality -of-life index , and maximal urinary flow rate . RESULTS After 6 weeks of naftopidil administration , significant improvements in daytime and nighttime frequency , International Prostate Symptom Score , quality -of-life index , maximal flow rate , average flow rate , and bladder compliance were examined . On the International Prostate Symptom Score question naire , improvement in the sensation of the bladder not emptying and a reduction in nighttime frequency stood out . Moreover , detrusor overactivity was observed in 40 patients before the start of treatment and was eliminated in 31 . The effective rate of this study was 69.7 % ( 85/122 ) . CONCLUSIONS Naftopidil has novel effects in patients with BPH whose main complaints are storage and voiding symptoms , especially that of nocturia of > or=3 times , as well as in patients with a low compliance bladder and detrusor overactivity , who did not respond to tamsulosin
Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .